Kaposi's sarcoma-associated herpesvirus (KSHV), also called human herpesvirus 8 (HHV8), is a double-stranded DNA virus that causes Kaposi's sarcoma, primary effusion lymphomas, and multicentric Castleman's disease (1-3). Like other herpesviruses, KSHV exhibits both latent and lytic modes of infection, persisting predominantly in the latent state in which only a subset of the viral proteins are expressed, including the latency-associated nuclear antigen (LANA) protein (4-8). Although the expression of latent proteins plays a critical role in inducing and maintaining KSHV latency, the infected cells are primed early during the primary infection to retain the viral genomes and induce tumors (9). During the primary infection, KSHV undergoes a short lytic replication cycle that transcribes an array of viral genes, which have been shown to modulate various pathways for establishing the latent infection (9). In addition, a small fraction (1 to 5%) of the infected cells spontaneously undergo lytic reactivation to produce infectious virions, which is likely to be essential for increasing the population of infected cells and inducing viral pathogenesis (10-13).The infection of target cells with KSHV is a complex multistep process involving a variety of host cell surface receptors and multiple viral glycoproteins. Irrespective of its mechanism of entry, for a successful infection, KSHV must overcome the obstacles it encounters during the transportation of viral capsids from the plasma membrane into the nucleus. The main obstacles include